Detalhe da pesquisa
1.
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children.
Int J Infect Dis
; 126: 164-173, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36403819
2.
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
Vaccine
; 40(13): 2068-2075, 2022 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35164986
3.
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial.
Lancet Respir Med
; 10(8): 785-795, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35691295
4.
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults.
Med
; 3(11): 760-773.e5, 2022 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35998623
5.
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
Vaccine
; 40(31): 4220-4230, 2022 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35691871